The 2024 increase is the same as last year.The foundation’s annual survey of employer health benefits also found that only 18 ...

Bayer announced today that the FDA has accepted their new drug application (NDA) for menopause drug, elinzanetant, to treat ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Studies measuring patient preference stacked up in subcutaneous administration’s favor, according to a recently published ...

The higher dose led to a more rapid decline in an important marker of neurodegeneration, according to a Biogen news release ...

The results showed that 26% of patients who received tulisokibart achieved clinical remission at week 12 compared with 1% of ...